Dietary phosphate restriction suppresses phosphaturia but does not prevent FGF23 elevation in a mouse model of chronic kidney disease

Kidney International

Volumn 84, Issue 4, 2013, Pages 713-721

  Zhang, Shiqin ^a   Gillihan, Ryan ^a   He, Nan ^b   Fields, Timothy ^a,b   Liu, Shiguang ^c   Green, Troy ^a   Stubbs, Jason R ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c Genzyme   (United States)

Author keywords

chronic kidney disease; ESRD; FGF23; mineral metabolism; phosphate

Indexed keywords

CALCITRIOL; CREATININE; FIBROBLAST GROWTH FACTOR 23;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; CALCIUM TRANSPORT; CHRONIC KIDNEY DISEASE; CREATININE BLOOD LEVEL; CYP24A1 GENE; CYP27B1 GENE; DIET RESTRICTION; DISEASE SEVERITY; FGF23 GENE; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC TRANSCRIPTION; GLOMERULOSCLEROSIS; KLOTHO GENE; MINERAL METABOLISM; MOUSE; NONHUMAN; PHOSPHATE INTAKE; PHOSPHATURIA; PHOSPHORUS URINE LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN METABOLISM; URINARY EXCRETION; URINE LEVEL; VITAMIN BLOOD LEVEL;

25-HYDROXYVITAMIN D3 1-ALPHA-HYDROXYLASE; ADMINISTRATION, ORAL; ANIMALS; AUTOANTIGENS; BONE AND BONES; COLLAGEN TYPE IV; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLAST GROWTH FACTORS; GLUCURONIDASE; HYPOPHOSPHATEMIA, FAMILIAL; KIDNEY; MALE; MICE; MICE, KNOCKOUT; NEPHRITIS, HEREDITARY; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; STEROID HYDROXYLASES; VITAMIN D;

EID: 84885319491     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.194     Document Type: Article

References (29)

1. Liu S, Tang W, Zhou J et al. Fibroblast growth factor 23 is a counterregulatory phosphaturic hormone for vitamin D. J Am Soc Nephrol 2006; 17: 1305-1315.
2. Liu S, Zhou J, Tang W et al. Pathogenic role of Fgf23 in Hyp mice. Am J Physiol Endocrinol Metab 2006; 291: E38-E49.
3. Rodriguez-Ortiz ME, Lopez I, Munoz-Castaneda JR et al. Calcium deficiency reduces circulating levels of FGF23. J Am Soc Nephrol 2012; 23: 1190-1197.
4. Kawata T, Imanishi Y, Kobayashi K et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007; 18: 2683-2688.
5. Ix JH, Shlipak MG, Wassel CL et al. Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 2010; 25: 993-997.
6. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
7. Stubbs JR, Egwuonwu S. Is fibroblast growth factor 23 a harbinger of mortality in CKD? Pediatr Nephrol 2012; 27: 697-703.
8. Juppner H. Phosphate and FGF-23. Kidney Int Suppl 2011; 121: S24-S27.
9. Wolf M. Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427-1435.
10. Stubbs JR, He N, Idiculla A et al. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease. J Bone Miner Res 2012; 27: 38-46.
11. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218.
12. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998; 31: 607-617.
13. Gutierrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584-592.
14. Miner JH, Sanes JR. Molecular and functional defects in kidneys of mice lacking collagen alpha 3(IV): implications for Alport syndrome. J Cell Biol 1996; 135: 1403-1413.
15. Andrews KL, Mudd JL, Li C et al. Quantitative trait loci influence renal disease progression in a mouse model of Alport syndrome. Am J Pathol 2002; 160: 721-730.
16. Hasegawa H, Nagano N, Urakawa I et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010; 78: 975-980.
17. Gutierrez OM. Fibroblast growth factor 23 and disordered vitamin D metabolism in chronic kidney disease: updating the "trade-off" hypothesis. Clin J Am Soc Nephrol 2010; 5: 1710-1716.
18. Helvig CF, Cuerrier D, Hosfield CM et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010; 78: 463-472.
19. Posner GH, Helvig C, Cuerrier D et al. Vitamin D analogues targeting CYP24 in chronic kidney disease. J Steroid Biochem Mol Biol 2010; 121: 13-19.
20. Baxter LA, DeLuca HF. Stimulation of 25-hydroxyvitamin D3-1alphahydroxylase by phosphate depletion. J Biol Chem 1976; 251: 3158-3161.
21. Tanaka Y, Deluca HF. The control of 25-hydroxyvitamin D metabolism by inorganic phosphorus. Arch Biochem Biophys 1973; 154: 566-574.
22. Hughes MR, Brumbaugh PF, Hussler MR et al. Regulation of serum 1alpha,25-dihydroxyvitamin D3 by calcium and phosphate in the rat. Science 1975; 190: 578-580.
23. Siomou E, Challa A, Printza N et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. Pediatr Nephrol 2011; 26: 1105-1114.
24. Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011; 22: 124-136.
25. Hu MC, Shi M, Zhang J et al. Klotho: a novel phosphaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J 2010; 24: 3438-3450.
26. Morishita K, Shirai A, Kubota M et al. The progression of aging in klotho mutant mice can be modified by dietary phosphorus and zinc. J Nutr 2001; 131: 3182-3188.
27. Marsell R, Krajisnik T, Goransson H et al. Gene expression analysis of kidneys from transgenic mice expressing fibroblast growth factor-23. Nephrol Dial Transplant 2008; 23: 827-833.
28. Cosgrove D, Meehan DT, Grunkemeyer JA et al. Collagen COL4A3 knockout: a mouse model for autosomal Alport syndrome. Genes Dev 1996; 10: 2981-2992.
29. David V, Martin A, Hedge AM et al. Matrix extracellular phosphoglycoprotein (MEPE) is a new bone renal hormone and vascularization modulator. Endocrinology 2009; 150: 4012-4023.